Clinical Trials Logo

Apnea clinical trials

View clinical trials related to Apnea.

Filter by:

NCT ID: NCT06331819 Recruiting - Clinical trials for Obstructive Sleep Apnea

Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms.

VasOSA
Start date: March 10, 2024
Phase:
Study type: Observational

The goal of this prospective cohort study is to study patients referred for sleep study by in-lab polysomnography in the Jordan University Hospital and the Jordan Hospital. The main aims are: - To prospectively obtain demographic and clinical information of patients referred for a sleep study. - To determine the diagnostic value of facial discoloration as potential marker for obstructive sleep apnea to increase detection rate for the condition. - To establish a correlation between obstructive sleep apnea and vasovagal symptoms with resulting increased smoking tendency and study the effect of treatment on the disorders. - To determine the association between timing of appearance of obstructive sleep apnea symptoms and initiation of smoking.

NCT ID: NCT06330116 Enrolling by invitation - Clinical trials for Sleep Apnea, Obstructive

Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea

SNORT
Start date: March 29, 2024
Phase: N/A
Study type: Interventional

Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these different training methods can reduce snoring and affect the level of sleepiness and quality of life. Study design The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase, and follow-up measurements. Methods 141 consecutive adult subjects, 71 men and 70 women referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sites, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the three different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Participants in Umeå will be randomized to either training with IQoro or serving as controls. Participants in Köge will be randomized to either training with Exciteosa, group training, or controls. The primary outcome is a change in AHI before and after three months of training with the different methods according to overnight ambulatory sleep apnea recordings. The secondary outcomes are change in snoring frequency, sound level dB (A) according to a questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ), daytime sleepiness using the Epworth Sleepiness Scale (ESS), change in quality of life using the short form -36 (SF-36) and muscle strength in tongue before and after treatment.

NCT ID: NCT06319612 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Effectiveness of Stellate Ganglion Block for the Treatment of Obstructive Sleep Apnea

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are: • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

NCT ID: NCT06319482 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

The Adherence of Proactive Sleep Apnea Therapy

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are: 1. To compare the adherence of proactive therapy and conventional Automatic-PAP (APAP) therapy short-term (3 months) and long-term (12 months) for newly diagnosed OSA patients. 2. To compare health outcomes (AHI, nightly pressure, and patient-reported outcomes) between proactive therapy and conventional APAP therapy.

NCT ID: NCT06317701 Recruiting - Clinical trials for Obstructive Sleep Apnea

Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation

Start date: April 4, 2024
Phase:
Study type: Observational

The purpose of this study is to determine if the treatment of Obstructive sleep apnea (OSA) by hypoglossal nerve stimulation (HGNS) will alter glucose metabolism. The study team will also determine if the treatment of Obstructive sleep apnea (OSA) by (hypoglossal nerve stimulation) HGNS will alter predictors of cardiovascular outcomes.

NCT ID: NCT06313840 Recruiting - Heart Failure Clinical Trials

Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients With Heart Failure With Reduced or Mildly Reduced Left Ventricular Ejection Fraction

COG01
Start date: August 21, 2023
Phase:
Study type: Observational

Study to assess the prevalence of central sleep apnea in patients with heart failure with reduced or mildly reduced left ventricular ejection fraction (LVEF <50%) followed by case-control study to assess the link between central sleep apnea and cognitive function

NCT ID: NCT06312956 Recruiting - Clinical trials for Obstructive Sleep Apnea

Multidimensional Evaluation of Patients' Affected by Obstructive Apnea Syndrome (OSAS) Before and After Ventilotherapy

MULTI-OSAS
Start date: February 29, 2024
Phase:
Study type: Observational

This observational study aims to evaluate multiple dimensions of health in patients with Obstructive Sleep Apnea Syndrome (OSAS), before and after three weeks of ventilotherapy. Specifically, the study aims to identify pre- vs post-treatment differences in the following domains: - cognitive performance - blood expression of biomarkers related to neurodegeneration - psychosocial wellbeing Thus, patients will complete the following evaluations before (T0) and after (T1) ventilotherapy: - neuropsychological standard assessment - blood sampling - psychosocial self-reported questionnaires

NCT ID: NCT06311045 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

NCT ID: NCT06306651 Recruiting - Clinical trials for Obstructive Sleep Apnea

High Flow Nasal Cannula and Conventional Oxygen Therapy in the Postoperative Management of Patients With Mild to Moderate Obstructive Sleep Apnea

Start date: March 16, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the effectiveness of conventional oxygen therapy oxygen and high-flow nasal cannula therapy on oxygen saturation (SpO2), measuring number of SpO2 drop >4% of base line oxygen saturation (o2 desaturation index), length of the ICU stay, and the need of use supplemental continuous positive airway pressure (CPAP) support in any of the study groups in the postoperative ICU setting.

NCT ID: NCT06295562 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea of Adult

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This study will recruit 66 patients with obstructive sleep apnea, comprising 33 men and 33 women, who have been referred to the sleep center by their doctors for polysomnograms (PSG). The subjects will undergo two overnight sleep PSG sessions at the sleep center. The interval between the two examinations will be at least 7 days, during which they will receive both a placebo and medication conditions, administered 1 hour before bedtime. The study drugs will include: (1) atomoxetine 80 mg and oxybutynin 5 mg; or (2) venlafaxine 37.5 mg; or (3) atomoxetine 80 mg and trazodone 100 mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.